Find Clinical Trials

Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.

This search will output a list of trials for which you may be eligible based on the criteria you enter.

Matching Trials

For more detailed information please click on the clinical trial number and you will be taken to the website.
For a key to the icons and text used in the Results column, please click here.
To learn more about our trial annotation process, results assignments, and the criteria used to highlight drugs with promising results, please click here.

  Clinical Trial Phase Eligible Participant Official Title Location Drugs in Trial Results
NCT04239014IIRecurrent platinum sensitive ovarian cancer with PARP inhibitor maintenance therapy following last platinum-based therapyA Phase 2 Randomized, Multi-Centre Study to Investigate the Efficacy and Tolerability of a Second Maintenance Treatment in Patients With Platinum Sensitive Relapsed Epithelial Ovarian Cancer, Who Have Previously Received PARP Inhibitor Maintenance TreatmentAK, CA, CT, FL, GA, KY, LA, MI, MN, NJ, NY, OH, OK, OR, PA, RI, SC, SD, TX, VA, WAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CeralasertibAZD6738, ATR kinase inhibitor AZD6738ATR kinase inhibitorClinical Trials
OlaparibAZD2281, LynparzaPARP inhibitorApproved in Ovarian Cancer
NCT04377087IIPlatinum sensitive ovarian cancer with response to most recent Pt-based therapy (maintenance)Phase IIA Trial of Delayed Initiation of Olaparib Maintenance Therapy in Platinum Sensitive Recurrent Ovarian CancerPAView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
OlaparibAZD2281, LynparzaPARP inhibitorApproved in Ovarian Cancer
NCT02737787IRecurrent ovarian cancer with CR in second or greater remissionA Phase I Study of Concomitant WT1 Analog Peptide Vaccine or NY-ESO-1 Overlapping Peptides Vaccine in Combination With Nivolumab in Patients With Recurrent Ovarian Cancer Who Are in Second or Greater RemissionNJ, NYView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Galinpepimut-SSLS 001, WT-1 analog peptide vaccine SLS-001Immune response against cancer expressing WT1Clinical Trials
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NY-ESO1 vaccineImmune response against cancer expressing NY-ESO-1Clinical Trials

If you have any questions or would like help with your search, please call us at: 858-264-5124 or email us at